Vahanian Alec, Alfieri Ottavio R, Al-Attar Nawwar, Antunes Manuel J, Bax Jeroen, Cormier Bertrand, Cribier Alain, De Jaegere Peter, Fournial Gerard, Kappetein Arie Pieter, Kovac Jan, Ludgate Susanne, Maisano Francesco, Moat Neil, Mohr Friedrich-Wilhelm, Nataf Patrick, Pierard Luc, Pomar José Luis, Schofer Joachim, Tornos Pilar, Tuzcu Murat, van Hout Ben, von Segesser Ludwig K, Walther Thomas
Hôpital Bichat, Paris, France.
Eur J Cardiothorac Surg. 2008 Jul;34(1):1-8. doi: 10.1016/j.ejcts.2008.04.039. Epub 2008 May 27.
To critically review the available transcatheter aortic valve implantation techniques and their results, as well as propose recommendations for their use and development.
A committee of experts including European Association of Cardio-Thoracic Surgery and European Society of Cardiology representatives met to reach a consensus based on the analysis of the available data obtained with transcatheter aortic valve implantation and their own experience. The evidence suggests that this technique is feasible and provides haemodynamic and clinical improvement for up to 2 years in patients with severe symptomatic aortic stenosis at high risk or with contraindications for surgery. Questions remain mainly concerning safety and long-term durability, which have to be assessed. Surgeons and cardiologists working as a team should select candidates, perform the procedure, and assess the results. Today, the use of this technique should be restricted to high-risk patients or those with contraindications for surgery. However, this may be extended to lower risk patients if the initial promise holds to be true after careful evaluation.
Transcatheter aortic valve implantation is a promising technique, which may offer an alternative to conventional surgery for high-risk patients with aortic stenosis. Today, careful evaluation is needed to avoid the risk of uncontrolled diffusion.
批判性地回顾现有的经导管主动脉瓣植入技术及其结果,并对其应用和发展提出建议。
一个由包括欧洲心胸外科学会和欧洲心脏病学会代表在内的专家组成的委员会召开会议,基于对经导管主动脉瓣植入所获现有数据的分析以及他们自身的经验达成共识。证据表明,该技术对于高危或有手术禁忌证的严重症状性主动脉瓣狭窄患者是可行的,并且能在长达2年的时间里改善血流动力学和临床状况。主要问题仍集中在安全性和长期耐用性方面,这些都有待评估。外科医生和心脏病专家应作为一个团队来挑选患者、实施手术并评估结果。目前,这项技术的应用应仅限于高危患者或有手术禁忌证的患者。然而,如果经过仔细评估后最初的预期被证明是正确的,那么其应用范围可能会扩大到低风险患者。
经导管主动脉瓣植入是一项有前景的技术,对于高危主动脉瓣狭窄患者而言,它可能是传统手术的一种替代方案。目前,需要进行仔细评估以避免出现不受控制的扩散风险。